Developmental Medicine and Child Neurology 2006-07-01

Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.

Sarah E Aylett, Helen Cross, Dave Berry

Index: Dev. Med. Child Neurol. 48(7) , 612-5, (2006)

Full Text: HTML

Abstract

A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0.75mg/kg/day. Concurrent antiepileptic medication was lamotrigine at 13mg/kg/day. Clobazam plasma levels were within the normal range, while N-desmethylclobazam (DCLB) concentrations were between five and seven times above the upper limit of the normal range. The plasma elimination half-life for DCLB was prolonged, suggesting a genetic variability in DCLB metabolism leading to toxicity. Reduction in the dose of clobazam to 0.3mg/kg/day was associated with resolution of the non-epileptic neurological symptoms, reduction in DCLB plasma levels, and maintenance of seizure control.


Related Compounds

Related Articles:

Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.

2010-11-01

[Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)]

Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.

2005-09-05

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)]

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.

2004-12-01

[Brain Dev. 26(8) , 530-4, (2004)]

Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD.

1996-11-01

[Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)]

HPLC method for simultaneous determination of clobazam and N-desmethylclobazam in human serum, rat serum and rat brain homogenates.

1989-03-01

[Biomed. Chromatogr. 3(2) , 79-81, (1989)]

More Articles...